MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
4.400
-0.190
-4.14%
After Hours: 4.420 +0.02 +0.45% 19:39 05/05 EDT
OPEN
4.530
PREV CLOSE
4.590
HIGH
5.48
LOW
4.160
VOLUME
796.20K
TURNOVER
--
52 WEEK HIGH
13.53
52 WEEK LOW
3.180
MARKET CAP
239.39M
P/E (TTM)
-0.8136
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALMS last week (0428-0502)?
Weekly Report · 18h ago
Acelyrin urges stockholders to vote for proposed merger with Alumis
TipRanks · 4d ago
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition
TipRanks · 5d ago
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis
Seeking Alpha · 6d ago
Largest borrow rate increases among liquid names
TipRanks · 04/28 12:49
Weekly Report: what happened at ALMS last week (0421-0425)?
Weekly Report · 04/28 12:49
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 04/22 13:37
Alumis Price Target Cut to $14.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 04/22 10:46
More
About ALMS
More
Alumis Inc. is a clinical-stage biopharmaceutical company. The Company is developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases, such as monotherapy or combination therapies. It is focused on developing its two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. Its ESK-001 is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases.
Recently
Symbol
Price
%Change

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.